Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 34Not yet recruiting 18Unknown 15Completed 10Withdrawn 6Terminated 5Active not recruiting 5Suspended 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Melanoma 1Locally Advanced Non-small Cell Lung Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Immunotherapy × Clear all
NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

West China Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

NCT04242329 2024-01-26

SUMMIST

Vastra Gotaland Region

Phase 2 Withdrawn
Dermatologic

Melanoma

NCT04650490 2023-03-02

STICk-IM-NSCLC

Duke University

Phase 2 Withdrawn
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

NCT05245760 2022-11-08

CRATER

University of Kentucky

Phase 2 Withdrawn
Gastrointestinal

Esophageal Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡